New hope for tough kidney cancers: testing a powerful drug combo
NCT ID NCT07277972
Summary
This study is testing a new combination of drugs for people with advanced kidney cancer that has worsened after their first treatment. It combines an immunotherapy (iparomlimab and tuvonralimab) with one of two targeted drugs (lenvatinib or axitinib). The main goal is to see if this combination can shrink tumors and control the cancer for people who have few other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RCC, RENAL CELL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.